Respiratory Disease Research

The respiratory system consists of the lungs, airways, diaphragm, trachea (windpipe) and pharynx (throat) and its primary function is the exchange of oxygen and carbon dioxide- breathing in and out. Between 6 and 10 liters of air are brought in and out of the lungs and 0.3 liters of oxygen are transferred from the alveoli to the blood per minute.

Respiratory Disease Research Products Areas

Products for Respiratory Disease Research - Page 19

Cat.No. Product Name Information/Activity
BCN2173 Gefitinib Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.
BCC7662 JNJ 28871063 hydrochloride 944342-90-9
BCN1808 Lavendustin A Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of tyrosine kinase, with an IC50 of 11 ng/mL for EGFR-associated tyrosine kinase. It suppresses VEGF-induced angiogenesis and blocks the induction of LTPGABA-A.
BCC6702 Methyl 2,5-dihydroxycinnamate 63177-57-1
BCC7434 PD 158780 PD158780 is a potent EGFR family inhibitor with IC50s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.
BCC7486 PP 3 5334-30-5
BCC4513 Mubritinib (TAK 165) Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.
BCC6703 Tyrphostin B44, (-) enantiomer 133550-32-0
BCC6704 Tyrphostin B44, (+) enantiomer 133550-37-5
BCC2202 WHI-P154 WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC50s of 4 nM and 1.8 μM, respectively.